Vanda Pharmaceuticals' Phase III Clinical Study Of VQW-765 In Adults With Social Anxiety Disorder Did Not Meet Its Primary Endpoint; VQW-765 Was Safe And Well-Tolerated

Benzinga

2026.10.14 21:03 (GMT+0)

在Benzinga上打开